Survival outcomes of the NeoALTTO study (BIG 1–06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer
-
Published:2019-09
Issue:
Volume:118
Page:169-177
-
ISSN:0959-8049
-
Container-title:European Journal of Cancer
-
language:en
-
Short-container-title:European Journal of Cancer
Author:
Huober Jens, Holmes Eileen, Baselga José, de Azambuja Evandro, Untch Michael, Fumagalli Debora, Sarp Severine, Lang Istvan, Smith Ian, Boyle Frances, Xu Binghe, Lecocq Christophe, Wildiers HansORCID, Jouannaud Christelle, Hackman John, Dasappa Lokanatha, Ciruelos Eva, Toral Pena Juan Carlos, Adamchuk Hryhoriy, Hickish Tamas, de la Pena Lorena, Jackisch ChristianORCID, Gelber Richard D., Piccart-Gebhart Martine, Di Cosimo SerenaORCID
Funder
Roche Pfizer AstraZeneca Merck Novartis Ferring Ipsen Abbvie Amgen Astra Zeneca Celgene Daiji Sankyo Eisai Lilly Lilly Int. MSD Merck Mundipharma Myriad Genetics Odonate PUMA Biotechnology Roche Pharma Sanofi Aventis TEVA Pharmaceuticals Novartis Pharma GSK/Novartis Astra-Zeneca Servier Daiichi
Subject
Cancer Research,Oncology
Reference28 articles.
1. The biology of erbB-2/neu/HER-2 and its role in cancer;Hynes;Biochim Biophys Acta,1994 2. Targeted therapies in HER2-positive breast cancer – a systematic review;Schramm;Breast Care,2015 3. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy;Baselga;J Clin Oncol,2010 4. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer;Swain;N Engl J Med,2015 5. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stageHER2 positive breast cancer (NeoSphere): a multicenter, open label, phase 2 randomized trial;Gianni;Lancet Oncol,2012
Cited by
56 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|